Switching from Citalopram to Escitalopram: Not Recommended
Switching to escitalopram after citalopram failure is generally not recommended, as there is no evidence supporting improved efficacy when switching between these two closely related medications. Instead, consider switching to a structurally different second-generation antidepressant (such as bupropion, sertraline, or venlafaxine) or augmenting with another agent 1.
Why This Strategy Lacks Support
The key issue is that escitalopram is simply the S-enantiomer of citalopram 2, 3. While escitalopram contains only the therapeutically active component and research suggests it may be more potent than racemic citalopram at equivalent S-enantiomer doses 4, 5, 3, this does not translate into meaningful benefit for patients who have already failed an adequate trial of citalopram.
The Evidence on Switching Strategies
The 2016 American College of Physicians guideline examined switching strategies in treatment-resistant depression and found:
- Moderate-quality evidence showed no difference in response rates when switching between different second-generation antidepressants (bupropion vs. sertraline or venlafaxine; sertraline vs. venlafaxine) 1, 6
- The landmark STAR*D trial demonstrated that approximately 25% of patients achieved remission after switching medications, with no difference among bupropion SR, sertraline, and venlafaxine 6
- Importantly, these switching studies compared structurally distinct antidepressants, not closely related compounds like citalopram and escitalopram
Recommended Alternatives
When citalopram fails, evidence supports these approaches:
1. Switch to a Different Class
Switch to bupropion, sertraline, or venlafaxine rather than escitalopram 1, 6. These medications have different mechanisms and receptor profiles compared to citalopram, offering a genuine pharmacologic alternative.
2. Augmentation Strategy
Augment citalopram with bupropion (preferred over buspirone due to lower discontinuation rates and greater reduction in depression severity) 1. Low-quality evidence shows bupropion augmentation had 12.5% discontinuation due to adverse events versus 20.6% with buspirone (P < 0.001) 7.
3. Add Cognitive Therapy
Augment with cognitive behavioral therapy, which showed equivalent efficacy to medication augmentation strategies 1.
Clinical Considerations
The Escitalopram-Citalopram Relationship
While research demonstrates escitalopram's superior efficacy compared to citalopram in head-to-head trials 4, 5, these studies enrolled treatment-naïve patients. The R-enantiomer in citalopram may counteract the S-enantiomer's activity through allosteric modulation of the serotonin transporter 3. However, if a patient has already failed citalopram, they have essentially been exposed to escitalopram (the active component) without response—making a switch to pure escitalopram unlikely to provide benefit.
Important Caveats
Confirm adequate dosing and duration before declaring treatment failure: Patients should receive therapeutic doses for 6-8 weeks before modifying treatment 6. For citalopram, this typically means at least 20-40 mg daily (though note the 40 mg maximum due to QTc prolongation risk 8).
Assess adherence: Non-response may reflect poor adherence rather than true pharmacologic failure.
Consider severity: The 2023 ACP guideline network meta-analysis found no differences between second-generation antidepressants for switching strategies, reinforcing that medication choice should be based on tolerability, drug interactions, and patient preference rather than expected superior efficacy 7.
Safety Considerations
Both citalopram and escitalopram carry similar risks 8, 2:
- QTc prolongation (citalopram has a 40 mg/day maximum; escitalopram 20 mg/day maximum in most patients)
- Serotonin syndrome risk with concomitant serotonergic agents
- Discontinuation syndrome
- Sexual dysfunction
- Hyponatremia (especially in elderly)
Escitalopram may have slightly fewer drug-drug interactions due to less CYP450 enzyme inhibition compared to citalopram 8, but this alone does not justify switching in a non-responder.
Practical Algorithm
- Verify adequate trial: Citalopram 20-40 mg for ≥6-8 weeks with confirmed adherence
- If confirmed failure:
- First choice: Switch to bupropion SR, sertraline, or venlafaxine XR
- Alternative: Augment citalopram with bupropion SR
- Consider: Add cognitive behavioral therapy
- Avoid: Switching to escitalopram as the sole intervention
- Monitor: Assess response within 1-2 weeks of any change; modify again if no adequate response by 6-8 weeks 6
The bottom line: Escitalopram and citalopram are too pharmacologically similar to expect meaningful benefit from switching between them in treatment-resistant depression. Choose a genuinely different medication or augmentation strategy instead.